文献速递预防保健、筛查与疫苗老年与多病共存

延迟第二剂BNT162b2或mRNA-1273新冠疫苗的公共卫生影响:基于模拟智能体的建模研究

Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study.
PubMed 文献 · BMJ · 2021-05-12

该研究采用基于模拟智能体的建模方法,模拟美国某县10万人的接触网络,比较标准两剂接种与延迟第二剂优先首剂的策略。结果显示,在首剂疫苗效力≥80%且每日接种率≤0.3%人口时,延迟第二剂可降低180天累积死亡率;对65岁以下人群延迟第二剂在所有测试接种率下表现良好。

要点

  • 首剂效力≥80%且接种率≤0.3%/天时,延迟第二剂可降低累积死亡率。
  • 延迟第二剂对65岁以下人群在所有测试接种率下均表现良好。
  • 首剂效力70%时,标准与延迟策略的累积死亡率相近(235 vs 236/10万)。

核心结论

  • 在特定条件下,延迟第二剂疫苗接种策略可降低累积死亡率,至少对65岁以下人群如此。

研究设计与样本

  • 基于模拟智能体的建模研究,模拟基于美国真实县人口,包含10万个智能体,具有代表性的人口学和职业分布,通过职业、家庭和随机互动建立接触网络,模拟运行重复10次。

主要发现

  • 在90%、80%、70%首剂效力下,标准接种与延迟第二剂的每10万人中位累积死亡率分别为226 vs 179、233 vs 207、235 vs 236。
  • 延迟第二剂策略在疫苗效力≥80%且接种率≤0.3%人口/天时最优,绝对累积死亡率降低26至47/10万。
  • 对65岁以下人群延迟第二剂在所有测试接种率下均表现良好。

关键数值与推荐

  • 首剂疫苗效力设定为50%、60%、70%、80%、90%(接种后第12天起)。
  • 疫苗接种率设定为0.1%、0.3%、1%人口/天。
  • 主要结局为180天累积新冠死亡率、累积SARS-CoV-2感染和累积新冠住院。

临床怎么用

  • 在疫苗供应有限且首剂效力高、接种率低时,可考虑对65岁以下人群延迟第二剂以优先覆盖首剂。
  • 决策需结合当地疫苗效力、接种速率和年龄分布等条件。

局限性

  • 研究为模拟建模,结果依赖于模型假设和参数设置,需真实世界数据验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate population health outcomes with delayed second dose versus standard schedule of SARS-CoV-2 mRNA vaccination. DESIGN: Simulation agent based modeling study. SETTING: Simulated population based on real world US county. PARTICIPANTS: The simulation included 100 000 agents, with a representative distribution of demographics and occupations. Networks of contacts were established to simulate potentially infectious interactions though occupation, household, and random interactions. INTERVENTIONS: Simulation of standard covid-19 vaccination versus delayed second dose vaccination prioritizing the first dose. The simulation runs were replicated 10 times. Sensitivity analyses included first dose vaccine efficacy of 50%, 60%, 70%, 80%, and 90% after day 12 post-vaccination; vaccination rate of 0.1%, 0.3%, and 1% of population per day; assuming the vaccine prevents only symptoms but not asymptomatic spread (that is, non-sterilizing vaccine); and an alternative vaccination strategy that implements delayed second dose for people under 65 years of age, but not until all those above this age have been vaccinated. MAIN OUTCOME MEASURES: Cumulative covid-19 mortality, cumulative SARS-CoV-2 infections, and cumulative hospital admissions due to covid-19 over 180 days. RESULTS: Over all simulation replications, the median cumulative mortality per 100 000 for standard dosing versus delayed second dose was 226 v 179, 233 v 207, and 235 v 236 for 90%, 80%, and 70% first dose efficacy, respectively. The delayed second dose strategy was optimal for vaccine efficacies at or above 80% and vaccination rates at or below 0.3% of the population per day, under both sterilizing and non-sterilizing vaccine assumptions, resulting in absolute cumulative mortality reductions between 26 and 47 per 100 000. The delayed second dose strategy for people under 65 performed consistently well under all vaccination rates tested. CONCLUSIONS: A delayed second dose vaccination strategy, at least for people aged under 65, could result in reduced cumulative mortality under certain conditions.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Romero-Brufau S, Chopra A, Ryu AJ, et al. Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study. BMJ. 2021. PMID: 33980718. doi:10.1136/bmj.n1087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。